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Abstract
Background: Altered neuronal connectivity in peri-infarct tissue is an important contributor to both the
spontaneous recovery of neurological function that commonly develops after stroke and improvements in recovery
that have been induced by experimental treatments in animal models. Microglia and astrocytes are primary
determinants of the environment in peri-infarct tissue and hence strongly influence the potential for neuronal
plasticity. However, the specific roles of these cells and the timing of critical changes in their function are not well
understood. Minocycline can protect against ischemic damage and promote recovery. These effects are usually
attributed, at least partially, to the ability of this drug to suppress microglial activation. This study tested the ability
of minocycline treatment early after stroke to modify reactive responses in microglia and astrocytes and improve
recovery.
Methods: Stroke was induced by photothrombosis in the forelimb sensorimotor cortex of Sprague-Dawley rats.
Minocycline was administered for 2 days after stroke induction and the effects on forelimb function assessed up to
28 days. The responses of peri-infarct Iba1-positive cells and astrocytes were evaluated using immunohistochemistry
and Western blots.
Results: Initial characterization showed that the numbers of Iba1-positive microglia and macrophages decreased in
peri-infarct tissue at 24 h then increased markedly over the next few days. Morphological changes characteristic of
activation were readily apparent by 3 h and increased by 24 h. Minocycline treatment improved the rate of
recovery of motor function as measured by a forelimb placing test but did not alter infarct volume. At 3 days, there
were only minor effects on core features of peri-infarct microglial reactivity including the morphological changes
and increased density of Iba1-positive cells. The treatment caused a decrease of 57% in the small subpopulation of
cells that expressed CD68, a marker of phagocytosis. At 7 days, the expression of glial fibrillary acidic protein and
vimentin was markedly increased by minocycline treatment, indicating enhanced reactive astrogliosis.
Conclusions: Early post-stroke treatment with minocycline improved recovery but had little effect on key features
of microglial activation. Both the decrease in CD68-positive cells and the increased activation of astrogliosis could
influence neuronal plasticity and contribute to the improved recovery.
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Background
Spontaneous improvements in neurological function de-
velop progressively over the first few months following
stroke. Although multiple changes in the central nervous
system contribute to these improvements, alterations in
neuronal connectivity in tissue surrounding the infarct
are an important component [1–4]. Interventions that
have been found to improve neurological recovery after
stroke are often associated with additional increases in
peri-infarct neuronal plasticity that contribute to the
better outcomes [3–6]. Thus, there is considerable inter-
est in understanding factors that can modulate these
neuronal responses and promote beneficial changes in
connectivity in peri-infarct tissue.
Glial cells are major determinants of the peri-infarct
environment and a key influence on the capacity for
change in neuronal connectivity. The death of cells in
the developing infarct activates microglia in the sur-
rounding viable tissue producing marked changes in
morphology and gene expression that are initiated
within the first 24 h after stroke [7–11]. Changes in
astrocytic properties become prominent over the first
few days, triggered in part by substances released from
the microglia including cytokines and chemokines [12–
16]. Astrocytes are centrally involved in the development
of a glial scar that limits the spread of damage but can
also impede changes in neuronal outgrowth and con-
nectivity [14, 15]. Astrocytes and microglia also release
many other molecules that can influence recovery [11,
12, 15, 16]. The complexity of the response is further en-
hanced by the migration of blood-borne cells into the
infarct and surrounding tissue [17–19]. These include
monocytes that become tissue macrophages and share
many properties with resident microglia.
Manipulations of glial cells in the peri-infarct tis-
sue have the potential to improve or impair func-
tional recovery. The outcomes of such interventions
are likely to be greatly influenced by the timing of
the treatments and the specific cellular responses
that are targeted. In the present study, we aimed to
investigate the consequences of early modification of
peri-infarct microglial activation by treating with the
anti-inflammatory agent, minocycline, during the
first 2 days after stroke. Minocycline is a
second-generation tetracycline that has previously
been shown to reduce tissue infarction following
focal ischemia [20–24]. Moderate improvements in
neurological recovery have also been seen with min-
ocycline treatment protocols that do not significantly
modify infarct volume [25–27]. Although, minocy-
cline has been reported to influence multiple cellular
properties, an ability to impede activation of micro-
glia has been identified as a prominent feature of
the actions of this drug in models of stroke and
other brain diseases in animals [20, 28]. Thus, we
predicted that modifications to peri-infarct microglial
activation would be a major component of the cellu-
lar responses to early post-stroke treatment with
minocycline. This prediction was directly evaluated
based on measures derived from immunolabeling of
brain sections (as discussed further below). The ef-
fects of minocycline treatment on the subsequent
development of reactive astrogliosis and the recovery
of neurological function were also investigated.
Infarction in the cerebral cortex was produced by
photothrombosis within the forepaw sensorimotor cortex
in rats [29, 30]. This model of stroke, which results in per-
manent ischemia, typically generates more reproducible
infarcts than other approaches. The infarcts can be gener-
ated to occupy a relatively small proportion of the total
cerebral cortex, mimicking the situation for those strokes
in humans that have a better prospect for recovery [2, 31].
The photothrombotic model has been widely used to
identify changes in neuronal connectivity associated with
spontaneous improvements in function following stroke
and to investigate responses to treatments [2, 5]. The pat-
tern of changes in astrocytes and microglia is similar to
that in other models of stroke [32–35]. However, the in-
farct develops more rapidly in the photothrombotic
model. Thus, it is well suited to investigating the effects of
treatments on functional recovery without the complica-
tion of changes in infarct volume.
Previous investigations of the effects of minocycline
on microglia have usually assessed activation of these
cells based on qualitative observations of morphology
and cell density in brain sections immunolabeled to de-
tect either ionized calcium binding adaptor molecule 1
(Iba1) or CD11b. To better characterize the patterns of
activation of peri-infarct microglia in photothrombotic
stroke and the consequences of minocycline treatment,
we measured two aspects of Iba1 immunolabeling: (i)
the “circularity” of labeled cells, which is increased as a
result of the morphological changes associated with acti-
vation; (ii) the percentage of total area occupied by Iba1
immunolabeling (subsequently described as “area frac-
tion”), which in the peri-infarct tissue predominantly de-
tects alterations in microglial numbers arising from the
balance between cell migration, death, and proliferation.
These parameters reflect key components of microglial
activation that require complex changes in protein func-
tion and gene expression in these cells. As with almost
all markers for widely expressed microglial proteins,
antibodies against Iba1 also label macrophages derived
from circulating monocytes that invade the injured brain
tissue. Brain sections were co-immunolabeled for the
neuronal marker, NeuN, which clearly delineated the in-
farct at all time points studied, thus facilitating the iden-
tification of regions of interest for the analysis.
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Methods
Experimental design
Male Sprague-Dawley rats were obtained from La-
boratory Animal Services (University of Adelaide,
Adelaide, Australia). The animals were kept in a
temperature-controlled and humidity-controlled
room with a 12 h/12 h light/dark cycle and ad libi-
tum access to water and standard rat chow. Stroke
was induced in rats weighing between 270 and
340 g.
The study involved three major investigations: A.
Characterization of responses of Iba1-positive cells in
peri-infarct tissue during the first week following photo-
thrombotic stroke; B. Effects of lower-dose minocycline
treatment (as defined in the “Treatment with minocy-
cline” section) on forelimb function and cellular changes
during the first week following photothrombotic stroke;
C. Effects of higher-dose minocycline treatment (see
“Treatment with minocycline” section) on forelimb func-
tion (up to 28 days) and cellular changes following
photothrombotic stroke. The experimental protocols
and rats used in each of the three investigations are
summarized in Fig. 1.
For investigations of the effects of minocycline, rats
were randomly pre-assigned to either minocycline treat-
ment or vehicle treatment and all functional assess-
ments, imaging, and data analyses were performed by
investigators blinded to the treatment.
Induction of focal ischemia by photothrombosis
An infarct was produced in the forelimb motor cortex
using minor modifications of previously described proce-
dures [29, 30]. Briefly, rats were anesthetized with
100 mg/kg ketamine and 10 mg/kg xylazine i.p. A can-
nula was inserted into the femoral vein and used to
maintain anesthesia with additional injections of keta-
mine as required. The rat was placed in a stereotaxic
frame, the scalp was retracted, and the surface of the
skull cleared of periosteum and blood. A brass shim
stencil with a rectangular window (3 × 5 mm) was posi-
tioned over the forelimb motor cortex at 1.5 mm anter-
ior to bregma and 2.5 mm lateral to the midline. For
initial characterization of the response to the infarct and
studies of treatment with lower-dose minocycline (see
below), the infarct was produced on the right side of the
brain. For studies with the higher-dose of minocycline,
the infarct was produced on the side contralateral to the
limb used preferentially for a single pellet retrieval task
(see below).
The skull was transilluminated for stroke induction using
a 150 W light source (Intralux 5000; Volpi AG, Schlieren,
Switzerland) equipped with a green bandpass filter (532.5–
587.5 nm) and attached fiber-optic cable (6 mm diameter).
Prior to each procedure, the light intensity was measured at
the point of emission from the fiber-optic cable to ensure
that it was at least 140,000 lx. In studies testing the effects
of the higher dose of minocycline, a greater light intensity
between 160,000 and 170,000 lx was used, which contrib-
uted to longer-lasting functional deficits. The fiber-optic
cable was positioned directly over the window of the stencil
and as close as possible to the skull without contacting it.
Rose-bengal (10 mg/mL, 13 mg/kg) was injected via the
femoral vein cannula at 200 μL/min and the light illumi-
nated for 15 min.
Treatment with minocycline
In the initial investigations into the effects of minocycline,
the drug was administered i.p. at 50 mg/kg (10 mg/mL
minocycline hydrochloride in phosphate-buffered saline
(PBS), pH 7.4) or equivalent volume of PBS at 1 h and
24 h after stroke. The treatment regime was similar to
other studies that have reported significant effects in sup-
pressing microglial activation following stroke [20–22, 36].
Rats that were sacrificed at 24 h received only the first in-
jection at 1 h after stroke. This treatment protocol will be
referred to as “lower-dose minocycline treatment”.
In a subsequent series of experiments, a higher dosage
treatment was used and is referred to as “higher-dose
minocycline treatment”. The protocol was similar to
treatments used in the studies of Chu et al. [25] and
Kim et al. [37]. Minocycline (10 mg/mL in PBS) at
90 mg/kg or equivalent volume of PBS was administered
i.p. at 1 h after stroke induction and then at 50 mg/kg at
12, 24, 36, and 48 h.
Forelimb placing test
The forelimb placing response as described by Schallert
and Woodlee [38] was used as a criterion for inclusion
in the study and as the primary measure of recovery of
forelimb motor response after stroke. Each rat was han-
dled by an investigator for at least 10 min per day on
three separate days leading up to the surgical induction
of photothrombotic stroke. During these sessions, rats
were placed on the testing platform for a few minutes
and were given approximately five trials of each variant
of the forelimb placing task.
For testing, the rat was held firmly by the torso in both
hands such that all four limbs were hanging freely in
space. The placing response in the forelimb was assessed
by brushing the vibrissae of the rat against the test plat-
form. The trial was scored as a success if the rat placed
the forelimb on the platform. Three variants of the test
were used. In the first, the rat was moved toward the
platform so that both sets of vibrissae were stimulated.
Subsequent tests involved stimulation of the vibrissae ip-
silateral and then contralateral to the limb being
assessed. Each forelimb was tested ten times with each
of the three stimuli and a total success score out of 30
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was calculated. Rats were initially tested at 3 h after
stroke induction. Those rats with a score greater than 15
at this time were excluded from the study for the initial
characterization of glial cell responses and investigations
of the lower-dose minocycline treatment. For the
higher-dose minocycline treatment, rats with a score
greater than 5 were excluded, in an attempt to further
restrict variability in the outcomes.
For studies of the effects of the higher dose of minocy-
cline, neurological function was also evaluated using a
cylinder test for forelimb asymmetry and a skilled
reaching task, although only the results for the cylinder
test have been presented (see below).
Cylinder test for forelimb asymmetry
Forelimb use for weight support during rearing while
rats were engaged in exploration in a Perspex cylinder
(20 cm diameter, 30 cm height) was evaluated as previ-
ously described [29, 39]. The exploratory behaviour of
rats was recorded with an Otek high-definition digital
video camera. For measurements at 7 to 28 days, record-




Fig. 1 Summary of experimental design for the three major phases of the study. a Characterization of responses of Iba1-positive cells in peri-
infarct tissue during the first week following photothrombotic stroke. The numbers of rats shown were all assessed using the forelimb placing
test. Perfusion-fixed tissue from four to six rats per time point was used to assess infarct volume and that from four rats per time point was used
for immunohistochemistry. b Effects of lower-dose minocycline treatment on forelimb function and cellular changes during the first week
following photothrombotic stroke. c Effects of higher-dose minocycline treatment on forelimb function (up to 28 days) and cellular changes
following photothrombotic stroke
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approximately 100 times (median values for treatment
groups at each time: 90 to 105; range for individual rats:
72 to 124 touches.) At 24 h, rats usually became less ac-
tive within the first few minutes in the cylinder and
fewer touches were recorded. (Median value of 37 for
minocycline treated rats and 36.5 for vehicle-treated
rats.) The percentage of affected limb usage was calcu-
lated as (the number of touches of the forepaw contra-
lateral to the infarct + half the number of simultaneous
placements/total paw placements) × 100.
Single pellet skilled reaching test
Rats were trained to retrieve a pellet through a narrow
slit in a single pellet reaching box and tested after stroke
for total success and first attempt success in retrievals
using the forelimb contralateral to the infarct as de-
scribed previously [29, 40]. To facilitate training, rats
were food restricted so that their body weight gradually
reached 90 to 95% of that expected with free access to
food. Rats were trained in daily 10-min sessions over 2
to 3 weeks up to the day prior to stroke induction. Initial
training allowed the paw preference for this task to be
identified. Subsequent training sessions led to improved
success in the task. At the conclusion of the training
period, median values for successful reaching for the
two groups exceeded 50% on a 20-trial test. Rats were
subsequently tested at 24 h and 7, 14, 21, and 28 days
after stroke induction. However, the extent of recovery
was highly variable between rats within groups. Thus,
the results were not useful in detecting possible differ-
ences in functional recovery following treatment and
have not been further discussed. Less variability on this
test was seen previously when additional training in
skilled reaching was provided during recovery [26].
The absence of such training was potentially a major
contributor to the variability seen in the present
study. Consistent with this possibility, our subsequent
investigations of other treatments (manuscripts in
preparation) indicated that the inclusion of further
training after the stroke greatly improved consistency
of responses within treatment groups enabling the
identification of functional differences.
Brain fixation and assessment of infarct volume
Rats were anesthetized with 100 mg/kg ketamine and
10 mg/kg xylazine i.p. and transcardially perfused at a
rate of 60 mL/min with 10 g/L NaNO2 in 0.01 M so-
dium phosphate buffer (pH 7.4) followed after approxi-
mately 3 min by 200 mL 40 g/L paraformaldehyde in
0.1 M sodium phosphate buffer (pH 7.4). The brains
were incubated in the same paraformaldehyde solution
overnight at 4 °C. Brains were cryoprotected by phased
transfer into 300 g/L sucrose in phosphate-buffered
saline (PBS, pH 7.4) containing 0.2 g/L sodium azide.
Coronal sections (20 μm) were prepared using a
cryo-microtome (Leica Systems, NSW, Australia).
Slide-mounted sections at 0.5-mm intervals through
the infarct were stained with 1 g/L cresyl violet in
water acidified with acetic acid (60 μL/L) and imaged
with a digital camera (Canon PowerShot A650 IS;
Canon Australia, NSW, Australia), together with a
calibration slide for scale. The area of the infarct in
each section, as identified by pale staining, was
measured using ImageJ version 1.49v [41]. Infarct volume
between sections was approximated using the trapezoidal
method (i.e., interval volumea,b = 1/2 × (areaa + areab) ×
interval distance) and summed to give total infarct
volume.
Antibodies
Antibodies for immunohistochemistry to detect Iba1
(goat polyclonal; catalog number ab5976), vimentin
(rabbit monoclonal; clone EPR3776; catalog number
ab92547), and CD68 (rabbit polyclonal; catalog number
ab125212) were from Abcam (Cambridge, UK), that for
detecting glial fibrillary acidic protein (GFAP; rabbit
polyclonal; catalog number G4546) was from
Sigma-Aldrich (St Louis, Mo) and for NeuN (mouse
monoclonal; clone A60; catalog number MAB377) was
from Millipore-Chemicon (Merck, Darmstadt,
Germany). Alexa-fluor-conjugated secondary antibodies
were from Thermo Fisher Scientific (Waltham, MA,
USA). For additional analysis of morphological changes
in Iba1-immunolabeled cells, the antibody to detect Iba1
was from Wako Pure Chemical (Osaka, Japan; catalog
#019-19741) and the biotinylated secondary antibody
was from Jackson ImmunoResearch (West Grove, PA,
USA; catalog #711-005-152).
For Western blot analysis, antibodies to detect GFAP
(rabbit polyclonal; catalog number G3893) and actin
(rabbit polyclonal; catalog number A2066) were from
Sigma-Aldrich; those for vimentin (rabbit monoclonal;
catalog number ab92547) were from Abcam and for
neurocan (mouse monoclonal; clone 650.24; catalog
number MAB5212) were from Millipore-Chemicon. A
peroxidase donkey anti-rabbit IgG (catalog number:
711-035-712) from Jackson ImmunoResearch was used
as secondary antibody.
Immunohistochemistry
Free-floating brain sections were blocked and perme-
abilized in 0.3% Triton-X100, 5% donkey serum in PBS,
pH 7.4 (blocking buffer) for 2 h at room temperature.
The sections were then incubated overnight at 4 °C in
primary antibodies diluted in blocking buffer (anti-Iba1
and anti-CD68, 1/1000, all other primary antibodies 1/
500). The sections were washed four times in PBS before
adding secondary antibodies (1/2000) and Hoechst
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33258 (1/1000; Thermo Fisher Scientific) diluted in PBS
and incubating for 2 h at room temperature on an or-
bital shaker. The sections were then washed four times
in PBS before being mounted on glass slides in Prolong®
Gold antifade mountant (Thermo Fisher Scientific) and
protected with a coverslip.
Image acquisition and analysis
For the initial characterization of changes in the micro-
glial response, images were obtained from Iba1 and
NeuN double-immunolabeled sections that incorporated
the eight regions of interest (ROIs) as shown in Fig. 2a.
This included ROIs on the lateral and medial edges of
the infarct as well as 1 mm from the infarct and at more
distant sites within the ipsilateral cerebral cortex. A sin-
gle ROI from the contralateral hemisphere was used for
comparison with the three sites close to the infarct. Two
additional contralateral ROIs corresponded with the
more distant sites in the ipsilateral cortex. The
peri-infarct ROIs were placed immediately adjacent to
the infarct within tissue where NeuN immunolabeling
was preserved. For all investigations of immunolabeling,
the reported results for each brain are the average of
values from two sections separated by at least 0.5 mm.
For analysis of circularity and the area fraction of Iba1
immunolabeling, image stacks were scanned at 1 μm
steps through the full thickness of the sections using a
Leica TCS SP5 confocal microscope (Leica Microsystems
Pty Ltd., NSW, Australia) with a × 20 objective lens.
Image analysis was performed on maximum intensity
projections generated in ImageJ version 1.49v. Back-
ground was reduced using the “subtract background
noise” function with “rolling ball radius” set at 100 pixels
and the sliding paraboloid function selected. Mean back-
ground fluorescence intensity was determined by aver-
aging the fluorescence intensity at five sites that were
devoid of cells. The threshold for subsequent image ana-
lysis was set at twice the mean background fluorescence
intensity rounded down to the nearest integer.
ROIs with dimensions of 500 × 500 μm were analyzed.
The ROIs were analyzed using the “Analyze Particles” func-
tion in ImageJ to obtain measures of “particle count,”
Fig. 2 Tissue damage and functional changes following photothrombotic stroke. a Cresyl-violet stained coronal section of a rat brain at 24 h after
induction of photothrombotic stroke showing the clearly defined infarct and the ROIs used for analysis of sections immunolabeled to detect Iba1.
The scale is in millimeters. b Cresyl-violet stained coronal section at 3 h after stroke induction. c Infarct volume over 7 days after stroke induction.
The infarct is fully developed by 24 h and then contracts substantially by 7 days (n = 4–6 per time point). d Coronal section of cerebral cortex
immunolabeled for NeuN at 3 h after stroke induction (scale bar = 500 μm). e Box plot of forelimb placing scores following stroke. Outlier values
are shown as circles; Blue = forelimb ipsilateral to infarct, Red = forelimb contralateral to infarct (n ≥ 5 per group)
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“average size,” “% area,” and “circularity.” For these analyses,
the particle size was set to a lower limit of 200 pixels. This
size limit corresponds to circular particles of approximately
12 μm in diameter and was chosen to exclude cell debris or
cells that were only partially within the section.
To complement the analysis of changes in morphology
using ImageJ, additional sections from rats at 24 h and
7 days after stroke were labeled with Iba1 and a biotinyl-
ated secondary antibody [42]. ROIs as shown in Fig. 2a
were analyzed using Neurolucida morphology software
(version 8; MBF Bioscience, VT, USA) to obtain mea-
sures of cell area, cell perimeter, and soma area of the
Iba1-labeled cells [42].
For an initial characterization of changes in the
astroglial response, images were scanned from sections
immunolabeled for both vimentin and NeuN
double-immunolabeled sections using an Olympus IX71
fluorescence microscope with a 4-times objective lens.
This analysis was limited to the peri-infarct tissue regions
on either side of the infarct and a corresponding contralat-
eral region. For the measurements, the peri-infarct ROIs
extended 500 μm from the edge of the infarct, as identi-
fied from the NeuN labeling and covered the full depth of
the cortical layer. Identical exposure settings were used to
capture all images for vimentin immunofluorescence.
Sections double-immunolabeled with CD68 and NeuN
were imaged using an Olympus AX70 fluorescence
microscope with a 10-times objective lens. In prelimin-
ary analysis, CD68-positive cells in peri-infarct tissue
were found to decrease sharply with distance from the
infarct. Thus, counts of CD68-positive particles were ob-
tained at two sites which are identified in the “Results”
section as “peri-infarct” and “peri-infarct + 0.3 mm.”
The peri-infarct tissue for this analysis extended 810 μm
along the border of the tissue and 270 μm into the tissue
with largely preserved NeuN labeling. This region was
analyzed as the sum of three adjacent 270 × 270 μm
boxes to facilitate alignment with the infarct border. The
peri-infarct + 0.3 mm site was analyzed as a single rect-
angular box with one edge located 0.3 mm from the in-
farct adjacent to the peri-infarct tissue. It extended a
further 270 μm into the intact tissue and was 810 μm in
length. There was no overlap of tissue between the two
regions that were examined.
Western blots
Rats were decapitated under anesthesia induced by i.p.
injection of ketamine (100 mg/kg) and xylazine (10 mg/
kg) at 7 days after stroke induction. The brain was rap-
idly removed from the skull and the infarct was identi-
fied from the paleness of the tissue on the surface of the
cortex. Cerebral cortex containing the infarct plus ap-
proximately 1.5 mm of surrounding tissue was dissected
out for analysis.
The tissue samples were homogenized in a buffer con-
taining 10 mM Tris, 1 mM EDTA, 0.32 M sucrose, pH
7.4, and a protease inhibitor cocktail (Sigma-Aldrich)
using a Retsch TissueLyser (Qiagen, Chadstone, Vic,
Australia) at a frequency of 30 Hz for 2 min. The ho-
mogenized samples were assayed for protein concentra-
tion using a Bio-Rad DC protein assay kit (Bio-Rad
Laboratories Gladesville, NSW Australia). Before gel
electrophoresis, samples used for neurocan blots were
pre-treated by incubating with chondroitinase ABC
(1 unit/mL) in 0.2 M Tris (pH 8.0) containing 0.3 M so-
dium acetate for 3 h at 37 °C [43].
Samples (20 μg protein in 20 μL) and molecular
weight standards (Precision Plus Protein™ Dual Color
Standards, #1610394; Bio-Rad Laboratories) were loaded
for gel electrophoresis (4–20% Criterion™ TGX
Stain-Free™ Protein Gel, #5678094; Bio-Rad Laborator-
ies) then transferred to PVDF membrane by electrophor-
esis (Trans-Blot® Turbo™ Transfer System with RTA
Midi LF PVDF Transfer Kit; Bio-Rad Laboratories). The
PVDF membranes were pre-treated by incubating in 5%
skim milk and 0.1% Tween 20 in PBS (pH 7.4) for 1 h at
room temperature. All antibodies were diluted (1:1000
for primary antibodies and 1:2000 for secondary anti-
bodies) in 2.5% skim milk and 0.05% Tween 20 in PBS
(pH 7.4). The membranes were incubated in primary
antibodies for 30 min at room temperature with regular
manual agitation and then overnight at 4 °C on an or-
bital shaker. They were then incubated in secondary
antibody for 2 h at room temperature. The bands were
developed by incubation in 5 mL ECL substrate (Clarity™
Western ECL Blotting Substrate; Bio-Rad Laboratories)
for 5 min at room temperature.
Chemiluminescence from the blots was captured digit-
ally on a Gel Doc™ EZ Imager (Bio-Rad Laboratories)
and the band intensities were analyzed using the Care-
stream Molecular Imaging Software (Version 5.0; Care-
stream Health, NY, USA). The intensity of vimentin or
GFAP bands were expressed relative to the bands for
actin. The intensity of the band for full-length neurocan
was expressed as a ratio to a fragment of this protein
with a molecular weight of approximately 150 kDa, that
was readily detectable in all samples. In mature brain,
neurocan is almost completely present as fragments gen-
erated by proteolysis [44]. In response to injury, the con-
tent of full-length neurocan increases greatly in
neighboring brain tissue, whereas the expression of the
truncated form is usually little changed [45–47].
Statistical analysis
Data from tests of neurological function are presented as
box plots. All other data are shown as mean ± standard
deviation. Statistical analyses were performed using the
SPSS software package (IBM SPSS Statistics for
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Windows. Version 23.0; IBM Corp., Armonk, NY, USA).
For assessing possible differences in recovery of function
using the forelimb placing test, the area under the plot
of test performance versus time was calculated including
all points between the assessment at 3 h after stroke in-
duction and the final assessment prior to euthanasia. For
the cylinder test, the area under the curve between 24 h
and 28 days was measured. Values were compared using
a non-parametric Mann-Whitney test. For other data,
which involved comparisons between multiple groups,
analysis of variance was used followed by post-hoc test-
ing with Tukey’s HSD test when statistically significant
differences were identified. Student’s t test was used for
comparisons between two groups. For all analyses, dif-
ferences with p < 0.05 were considered statistically
significant.
Results
Characterization of peri-infarct microglial responses
following stroke
Formation of the infarct was already well advanced at
3 h after induction of the photothrombotic stroke based
on the volume of tissue exhibiting pale staining with cre-
syl violet (Fig. 2b). The infarct volume reached a max-
imum by 24 h and had contracted greatly by 7 days (Fig.
2c). Immunolabeling for the neuronal marker, NeuN,
was largely lost in the infarct by 3 h after stroke induc-
tion (Fig. 2d). Thus, tissue on the edge of the infarct
retaining high-density NeuN labeling could be readily
delineated across the full range of times investigated.
Marked deficits in the function of the forelimb contra-
lateral to the infarct had developed within 3 h of stroke
induction as assessed from the forelimb placing test and
remained greatly impaired over the first 3 days (Fig. 2e).
By 7 days, recovery was substantial but incomplete in
most rats. The forelimb ipsilateral to the infarct pro-
duced near maximal scores at baseline and at all times
tested after stroke (with a median score of 30 at all time
points except for 2 days when the median score was 29).
Alterations of microglial morphology with loss of ram-
ification of cell processes were already apparent in
peri-infarct tissue at 3 h after stroke induction (Fig. 3a).
These changes contributed to a significant increase by
more than 80% in microglial circularity in one of the
peri-infarct ROIs, Ipsi01A when compared with equiva-
lent contralateral tissue (Fig. 3b). Circularity was not sig-
nificantly altered at other ROIs in the ipsilateral cortex
at this time. In both peri-infarct regions at 24 h, circular-
ity had increased more than 2.5-fold above values in the
contralateral tissue (Fig. 3c). Increases in circularity of
a b
c d
Fig. 3 Circularity of Iba1-positive cells after photothrombotic stroke. This parameter was measured in ROIs as defined in Fig. 2a. a Comparison of
Iba1-immunolabeled cells in peri-infarct tissue (Ipsi01A) and equivalent tissue (Contra01) in the hemisphere contralateral to the infarct at 3 h after
stroke induction. The scale bar = 100 μm. b Regional differences at 3 h. Insets show examples of processed images of Iba1-positive cells at an ROI
adjacent to the infarct (Ipsi01A) and in corresponding contralateral tissue (Contra01). c Regional differences at 24 h. Inset shows an example of a
processed image at Ipsi01A. d Time course of changes in peri-infarct regions (Ipsi01A and Ipsi01B), tissue 1 mm from the infarct (ipsi01A + 1 mm)
and corresponding contralateral tissue (Contra01) over the first 7 days. For panels b–d, n = 4 for each data point; *p < 0.05, **p < 0.01, ***p < 0.001
compared with the corresponding contralateral region (one-way ANOVA with Tukey’s HSD post-hoc test)
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peri-infarct microglia compared with the contralateral
regions largely persisted at 3 days and remained ele-
vated, albeit less so, at 7 days (Fig. 3d). Smaller increases
were also seen at 24 h in the damaged hemisphere at
sites up to several millimeters from the infarct (Ipsi02
and Ipsi03; Fig. 3c). A significant increase (p < 0.01) was
still present in Ipsi02 (0.079 ± 0.002) compared with cor-
responding contralateral tissue (0.065 ± 0.003) at 3 days
but no significant difference was seen in Ipsi03 at this
time. Neither of these ROIs differed significantly from
equivalent contralateral tissue at 7 days. However, a
small increase was observed in tissue 1 mm from the in-
farct (Fig. 3d).
To further characterize the morphological responses
of the microglia and aid in interpreting the findings
based on cell circularity, three additional features of the
Iba1-immunolabeled cells (cell area, cell perimeter, and
area of the cell soma) were measured in separate sec-
tions from the same rats at 24 h and 7 days (Fig. 4a–c).
Cell area and perimeter were significantly decreased in
the two peri-infarct regions at both 24 h and 7 days (Fig.
4a, b). These measures were also significantly decreased
at two of the sites more distant from the infarct (ipsi01A
+ 1 mm, ipsi03) at 24 h but not 7 days (Fig. 4 a, b; Add-
itional file 1: Figure S1 A and B) largely consistent with
the pattern of responses detected with circularity. The
third more distant region (ipsi02) was not significantly
different on these measures from the equivalent contra-
lateral region at 24 h but showed increases at 7 days
(Additional file 1: Figure S1 A and B). The area of the
soma was significantly increased at 24 h in the
peri-infarct tissue (Fig. 4c). This measure was not signifi-
cantly different at 7 days in these tissue regions or at any
time point in the more distant regions (Fig. 4c; Add-
itional file 1: Figure S1).
The area fraction of Iba1 immunolabeling was not sig-
nificantly changed in any region of the lesioned hemi-
sphere at 3 h after stroke onset. At 24 h, area fraction in
the peri-infarct ROI, ipsi01b, was significantly reduced
compared with corresponding tissue in the contralateral
region (Fig. 5a). The other peri-infarct ROI, ispi01a,
showed a trend toward a similar decrease but the differ-
ence was not statistically significant (p = 0.056). Both of
the peri-infarct ROIs had a significantly lower area frac-
tion (p < 0.05) compared with tissue located 1 mm from
the infarct (Fig. 5a). Additional analysis of the number of
Iba1-labeled particles in the peri-infarct tissue showed a
significant decrease (by 34%) in the two peri-infarct re-
gions compared with the equivalent contralateral tissue
(Fig. 5c). Some swelling of the affected tissue was ob-
served (Fig. 2a). Although this could contribute to the
reduction in area fraction, it was very much less than
the 50% increase in volume in peri-infarct tissue that
would fully account for the observed decrease in Iba1
immunolabeling. A loss of cells due either to cell death
or a migration of cells out of the peri-infarct tissue is
more likely to account for most of the change in area
fraction of Iba1 labeling at 24 h.
Fig. 4 Additional morphological features of Iba1-positive cells at 24 h and 7 days after photothrombotic stroke. a Cell area, b cell perimeter, and
c cell soma area. For panels a–c, n = 3 (7 days) or 4 (24 h); *p < 0.05, **p < 0.01, ***p < 0.001 compared with the corresponding contralateral
region, contra01 (one-way ANOVA with Tukey’s HSD post-hoc test). The ROIs that were analyzed are identified in Fig. 2a
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By 3 days, Iba1 labeling in peri-infarct tissue was
markedly increased compared with the contralateral
hemisphere and increased further by 7 days (Fig. 5b).
Particle counts at 3 days were also increased in
peri-infarct tissue indicating that changes in total cell
number were a major component of the increase in area
fraction in the peri-infarct tissue (Fig. 5c), In contrast,
the particle count at 7 days was not significantly differ-
ent from the equivalent contralateral tissue (Fig. 5c) des-
pite the continuing increase in area fraction. This
finding points to a limitation in the use of particle
counts at 7 days. At this time, but not the earlier time
points, the measure of particle size was increased in the
peri-infarct tissue (Fig. 5d). This change did not result
from increases in the size of individual cells. Rather it
reflected overlap between neighboring cells as the num-
bers markedly increased such that many cells were not
separately identified in the analysis. In contrast to the
large changes in the peri-infarct regions, tissue 1 mm
from the infarct and at more distant ipsilateral sites
(Ipsi02 and Ipsi03) showed no significant differences in
area fraction compared with corresponding regions in
the contralateral hemisphere at any of the time points
investigated (Fig. 5a, b).
The findings from the initial characterization indicated
that the circularity and area fraction of Iba1
immunoreactivity provide useful insights into important
aspects of the responses of microglia (and other
Iba1-positive cells) in the peri-infarct tissue following
photothrombotic stroke. For subsequent studies examin-
ing the effects of minocycline on recovery from photo-
thrombotic stroke, changes in these properties were
investigated only in a single peri-infarct region (equiva-
lent to Ipsi01A in Fig. 2a) as the responses in the two
peri-infarct regions were similar and changes outside the
peri-infarct region were either not seen or were smaller
and more short-lived.
Lower-dose minocycline treatment
Treatment with minocycline had no effect on infarct vol-
ume measured at 24 h to 7 days after stroke (Fig. 6a).
However, the treatment produced a more rapid recovery
of function as seen from a significantly better forelimb
placing response at 3 days (Fig. 6b). By 7 days, recovery
was substantial in both groups and the difference be-
tween the groups was not statistically significant. Placing
scores for the limb ipsilateral to the infarct were pre-
served with median scores of 30 for both treatment
groups at all times except at 3 h when median scores
were 28.5 and 29 for the two groups.
The changes in microglial circularity and area fraction
of Iba1 immunolabeling in the vehicle-treated group
Fig. 5 Changes in the pattern of Iba1-immunolabeling after photothrombotic stroke. a Regional differences in area fraction at 24 h. b–d Changes
in b area fraction, c Iba1-positive particle count, and d Iba1-positive particle size in peri-infarct tissue, tissue 1 mm from the infarct and
corresponding contralateral tissue between 3 h and 7 days. For all panels, n = 4 per data point; *p < 0.05, **p < 0.01, ***p < 0.001 compared with
Contra01 (one-way ANOVA with Tukey’s HSD post-hoc test). At 24 h, there was also a significant difference between each of the peri-infarct
regions and tissue located 1 mm from the infarct (at ipsi01a + 1 mm) for area fraction (Ipsi01a: p < 0.05; Ipsi01b: p < 0.01) and particle count
(p < 0.01 for each of the peri-infarct regions). The ROIs that were analyzed are identified in Fig. 2a
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were consistent with those seen in the initial
characterization. Circularity was maximally increased at
24 h, remained similarly elevated at 3 days, and was then
partially decreased by 7 days (Fig. 7a). For area fraction,
the initial decrease in peri-infarct tissue at 24 h to less
than 50% of the contralateral regions (Fig. 7b) was even
more pronounced than in the initial characterization. In
contrast to predictions based on previous reports of the
action of minocycline (see Introduction), this treatment
had no significant effect on either microglial circularity
or area fraction of immunolabeling between 24 h and
7 days after stroke (Fig. 7a, b).
Higher-dose minocycline treatment
The ability of minocycline to influence the activation of
peri-infarct microglia and recovery after stroke was fur-
ther assessed in rats that received a more intensive
treatment with this drug and were monitored for recov-
ery of neurological function for 28 days after stroke.
These rats were injected with an initial higher minocy-
cline dose (90 mg/kg) and received subsequent injec-
tions of 50 mg/kg at 12, 24, 36, and 48 h. For this part
of the study, a moderately higher intensity of the light
source was used to induce thrombosis. The inclusion
criteria were also made more stringent such that rats
with a placing score above 5 at 3 h were excluded
from further study.
The higher-dose minocycline treatment again did
not significantly affect infarct volume as assessed at
3 days after stroke induction (vehicle-treated: 17.20 ±
4.88; minocycline-treated: 18.56 ± 5.26 mm3, mean ±
SD, n = 6–7).
The modified procedures for stroke induction and/or
more stringent exclusion criteria led to longer-lasting
Fig. 7 Effects of lower dose minocycline treatment on responses of Iba1-positive cells after photothrombotic stroke. a Circularity and b area
fraction of Iba1-positive cells at 24 h, 3 days and 7 days following photothrombotic stroke (n = 4 to 8 per group). Two-way analysis of variance
detected highly significant differences between the contralateral and peri-infarct regions for both circularity and area fraction at all three time
points (p < 0.001). However, there were no significant effects of treatment on these parameters
Fig. 6 Effects of lower dose minocycline treatment on infarct volume and forelimb function after photothrombotic stroke. a Infarct volume: Two-
way analysis of variance revealed no significant effect of the minocycline treatment but a significant effect of time after stroke (p < 0.01; n = 4–8
per group). b Box plot of results from the forelimb placing test. Outliers are indicated with open circles. n = 6 per group for all times except 3 h
which shows the pooled data for rats in each of the subsequent groups. Rate of recovery was faster at 3 days *p < 0.05 (Minocycline vs vehicle,
Mann-Whitney U test analysis of area under curve for those rats tested at both 3 h and 3 days). No significant differences were detected at
other times
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deficits in the forelimb placing test in the vehicle-treated
group with most animals still exhibiting impairment at
28 days (Fig. 8a). Rats treated with minocycline recov-
ered more rapidly on this test (p < 0.05), with differences
particularly prominent at 7 and 14 days. There were no
significant changes in placing scores following stroke in-
duction for the forelimb ipsilateral to the infarct (with
median group scores of 28 to 30 for all time points for
both minocycline-treated and vehicle-treated rats).
Stroke also induced deficits in spontaneous use of the
forelimb contralateral to the infarct as assessed from the
cylinder test at 24 h after induction but these were less
severe than the initial changes in forelimb placing (Fig.
8b). The rate of recovery in the cylinder test task did not
differ significantly between the two treatment groups.
The more intense treatment with minocycline had
no significant effect on circularity of Iba1-positive
cells when assessed at 3 days (Fig. 9a). However,
small reductions were seen in area fraction in the
minocycline-treated group at this time (Fig. 9b). Simi-
lar decreases were found in both hemispheres indicat-
ing that this was a generalized change induced by the
minocycline and did not primarily reflect changes in
the specific microglial response to infarct formation.
The number of cells immunolabeled for CD68, a
marker of phagocytic activity in microglia and macro-
phages, were also measured at 3 days as
CD68-positive cells have previously been reported to
be altered by minocycline treatment (see “Discussion”
section). At this time, cells expressing CD68 were nu-
merous within the infarct (Fig. 10a). The density of
these cells in peri-infarct tissue was much lower than
in the infarct and was largely restricted to a region
immediately adjacent to the infarct. Compared with
the pattern of change in morphology and density of
Iba1-positive cells, the distribution of the
CD68-positive cells appeared to be much more tightly
associated with the rim of the infarct.
Minocycline treatment markedly decreased the num-
bers of CD68-positive cells by more than 50% in
peri-infarct tissue that was within 0.3 mm of the infarct
(Fig. 10b). At distances of more than 0.3 mm, there were
many fewer CD68-positive cells with similar numbers in
the two treatment groups.
Minocycline could also potentially modify downstream
responses in peri-infarct reactive astrogliosis that are at
least partly initiated by microglia [16]. This possibility
was initially assessed from measures of the content of
the cytoskeletal proteins, GFAP and vimentin, using
Western blotting of tissue samples containing the infarct
and peri-infarct tissue. Immunohistochemical detection
of these proteins in our samples revealed only low levels
of residual expression in the infarct. Thus, the major
portion of their content in the sampled tissue was de-
rived from the marked increase in expression in
peri-infarct cells. Vimentin was included in this analysis
because of the potential to provide a more sensitive indi-
cator of responses of reactive astrocytes than GFAP. In
the parenchyma of the normal mature brain, vimentin is
expressed by endothelia and perhaps other cells sur-
rounding blood vessels but is very rarely expressed by
astrocytes [48, 49]. Initial analysis of vimentin expression
based on both area fraction of vimentin immunolabeling
in tissue sections (Fig. 11a) and Western blots (Fig. 11b)
revealed large increases in peri-infarct tissue at 3 days
after stroke and further increases at 7 days to values that
were many times greater than in equivalent contralateral
tissue. The vimentin immunolabeling in the peri-infarct
tissue co-localized almost completely with GFAP label-
ing (Fig. 11c).
The content of both vimentin and GFAP at 7 days
after stroke induction was substantially increased (to
Fig. 8 Effect of higher-dose minocycline treatment on recovery of neurological function after photothrombotic stroke. Box plots of dysfunction
and recovery up to 28 days after photothrombotic stroke in a the forelimb placing test and b the cylinder test. Outliers are shown as open circles
(n = 8 per group). Recovery in the forelimb placing test was more rapid in minocycline-treated rats (p < 0.05; Mann-Whitney U test comparison of
area under curve for time points between 3 h and 28 days.) There was no significant difference in recovery between 24 h and 28 days for
performance in the cylinder test
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210% and 137% respectively) in the samples from
minocycline-treated rats (Fig. 11d) compared with those
injected with vehicle, indicating an increase in at least
some aspects of reactive astrogliosis. The content of
full-length neurocan, a proteoglycan that is largely pro-
duced by astrocytes and increases in response to brain tis-
sue damage [45–47], was also investigated. In normal
mature brain, this protein is almost all in the form of two
fragments derived by proteolysis from the full protein.
The content of the full-length protein increases markedly
in peri-infarct tissue following stroke [46]. In our study,
the ratio of full-length neurocan to a 150-kDa fragment of
this protein was not significantly different between the
minocycline-treated and vehicle-treated groups (Fig. 11e).
Discussion
The study provides evidence that early post-stroke mino-
cycline treatment can improve recovery of aspects of
neurological function in rats and that this was associated
with increases in indicators of reactive astrogliosis and
decreases in cells expressing CD68, a marker of micro-
glia/macrophage phagocytosis. However, the minocycline
treatment produced little, if any, suppression of
peri-infarct changes in microglial morphology or the
density of immunolabeling of these cells even though
modifications to these properties were predicted based
on previous investigations of the actions of this drug.
In addition, the characterization of microglial re-
sponses to cortical stroke identified a previously
a b
Fig. 10 Effect of higher-dose minocycline treatment on CD68-immunolabeled cells at 3 days after photothrombotic stroke. a Representative
image of CD68 (red) and NeuN (green) double-immunolabeled coronal section at the infarct boundary of a vehicle-treated rat. The infarct is
visible in the upper part of the image. The scale bar = 200 μm. b Effects of the higher-dose minocycline treatment on CD68-positive cells within
the peri-infarct tissue at 3 days following photothrombotic stroke (n = 6 to 7 per group). The CD68-positive particle count was assessed within
0.3 mm of the infarct (Peri-infarct) and between 0.3 and 0.6 mm from the infarct (Peri-infarct + 0.3 mm). Two-way analysis of variance revealed a
highly significant effect of both treatment (p < 0.01) and tissue location (p < 0.001) on CD68-positive particle count at 3 days after stroke. There
was also a strong interaction between the two factors (p < 0.001) reflecting the larger decrease in particle density induced by minocycline in the
tissue immediately adjacent to the infarct compared with the other regions examined
Fig. 9 Effect of higher-dose minocycline treatment on Iba1-positive cells at 3 days after photothrombotic stroke. a Circularity and b area fraction
of immunolabeling (n = 6 to 7 per group). Two-way analysis of variance revealed a statistically significant difference between the hemispheres for
both circularity and area fraction (p < 0.01) and a significant effect of the minocycline treatment on Iba1 area fraction (p < 0.05) but not on
circularity. For area fraction, there was no significant interaction between hemisphere and minocycline treatment
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unreported decrease in the area fraction of Iba1 immu-
nolabeling in peri-infarct tissue at 24 h that was primar-
ily due to fewer cells in this tissue. The decrease was
most likely the result of early migration of microglia into
the infarct and/or localized death of these cells. It was
followed by marked increases in Iba1-positive cells in
peri-infarct tissue at 3 to 7 days. Morphological changes
in these cells in peri-infarct tissue were readily apparent
within 3 h of stroke and could be detected from in-
creases in cell circularity. The increases in circularity
became more prominent by 24 h and were transiently
seen at sites more distant from the infarct.
Minocycline-treated rats showed improved recovery in
a forelimb placing test, which was the primary measure
of forepaw function in this study. This measure requires
no specific training of the rats and involves a motor re-
sponse to sensory stimulation. The improvement oc-
curred in the absence of changes in infarct volume and
is broadly consistent with reports of improved outcome





Fig. 11 Effects of higher-dose minocycline treatment on markers of reactive astrogliosis after photothrombotic stroke. a, b A large increase in
vimentin content in peri-infarct tissue over the first 7 days following photothrombotic stroke in untreated rats was detected by a area fraction of
vimentin-positive cells and b Western blotting. The area fraction of vimentin immunolabeling was markedly increased by 2 days and further
increased at 3 and 7 days after stroke (n = 4 per group at each time); *p < 0.05, **p < 0.01 vs. corresponding contralateral region (one-way ANOVA
with Tukey’s HSD). c Double immunolabeling of GFAP and vimentin in peri-infarct tissue at 3 days after photothrombotic stroke. Vimentin (red) is
expressed almost exclusively in cells also expressing GFAP (green). Yellow shows colocalization. The scale bar = 100 μm. d–e Effect of higher-dose
minocycline treatment on expression of astroglial proteins in samples containing infarct plus peri-infarct tissue at 7 days following
photothrombotic stroke (n = 6 per group). d The intermediate filament proteins, vimentin and GFAP. e Neurocan. The band intensities for
vimentin (54 kDa) and GFAP (50 kDa) were normalized to actin (45 kDa). There was a significant effect of minocycline treatment on both
vimentin and GFAP content (**p < 0.01). The intensity of bands for full-length neurocan (approx. 250 kDa) were determined relative to that of a
proteolytic fragment of this protein (approx. 150 kDa). No statistically significant effects were detected in the neurocan protein ratio in tissue from
the minocycline-treated rats compared with the vehicle-treated rats
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treatment in several other studies [25–27]. However,
treatment was limited to the first 2 days after stroke in
our study contrasting with these earlier studies showing
improved recovery [25–27], as well as some investiga-
tions of the neuroprotective effects of minocycline in ro-
dents [20, 22] and in humans [50]. Thus, the findings
suggest that cellular changes critical for recovery are ini-
tiated in the early stages after infarct formation and that
they can be modulated by minocycline treatment.
Long-term minocycline treatment has been shown
previously to moderately improve use of the affected
forepaw during spontaneous movement as assessed
using a cylinder test [27]. In contrast, no significant ef-
fect on performance in this test was detected in our
study. The differential effects on performance in the
forelimb placing test and cylinder test could be the re-
sult of a greater sensitivity of the placing test because
the initial stroke-induced deficits were larger. A similar
finding of significant improvement in a paw placing test
but not in a second test of neurological function (involv-
ing skilled reaching) was seen with environmental en-
richment following stroke in rats [51]. Thus, it is also
possible that plasticity can be more readily modified by
specific interventions in some components of the sen-
sorimotor neural pathways that are involved in the fore-
limb placing test.
Iba1 immunolabeling was selected as the primary
means to assess changes in microglia and macrophages
in the peri-infarct tissue because it allowed
time-dependent features of activation of these cells to be
assessed at sites adjacent to the infarct. The peri-infarct
tissue of interest was reproducibly identified based on
the pattern of co-labeling with the neuronal marker,
NeuN. The activation of microglia and macrophages in
peri-infarct tissue has also commonly been assessed in
previous studies based on the detection of changes in
cell-selective immunolabeling (see for example: [8, 9, 34,
35, 52]). However, most of the previous studies have
only provided qualitative descriptions of the pattern of
changes in markers of microglia and macrophages. The
detailed analysis of morphology by Morrison and Filosa
[8] and assessments of the numbers of proliferating
Iba1-positive cells by Li et al. [35] are notable excep-
tions, although the former study reported on changes in
peri-infarct tissue only at 8 and 24 h after temporary
focal ischemia.
The treatment with lower-dose minocycline delivered
in the first 24 h after stroke did not produce significant
differences in either circularity or Iba1 area fraction dur-
ing the first 7 days. The higher-dose treatment, which
was administered for the first 48 h after stroke, did pro-
duce changes in Iba1 area fraction. However, this was a
small effect and similar changes were seen in tissue from
the contralateral hemisphere. Thus, our findings suggest
that minocycline did not produce gross alterations in
these key responses to stroke in the Iba1-positive cells in
peri-infarct tissue. In other studies of the effects of min-
ocycline on responses to tissue damage in the brain, in-
cluding early influential investigations in models of focal
and global ischemia [20, 53], minocycline was reported
to greatly limit changes in microglial morphology or cell
distribution (as assessed qualitatively). The different re-
sponse to focal ischemia compared with that in the
present study is probably explained, at least in part, be-
cause minocycline produced decreases in cell loss and
infarct size in many of the earlier investigations of stroke
and such protective effects can secondarily reduce
microglial responses to ischemic damage [54, 55]. Other
factors could have contributed to the different outcome
including the initiation of treatment before stroke induc-
tion in some previous studies and the lack of procedures
to ensure consistent sampling of peri-infarct tissue as
was achieved with the co-labeling for NeuN in our
investigations.
In contrast to the limited effects of minocycline on the
measures of Iba1-immunolabeling in peri-infarct tissue,
there was a marked reduction at 3 days after stroke in-
duction in cells expressing CD68, a protein usually asso-
ciated with microglia and macrophages that are involved
in phagocytosis. This raises the possibility that
CD68-positive cells might have effects that limit recov-
ery following stroke. Decreases in numbers of cells ex-
pressing CD68 in peri-infarct tissue have also been
reported following other interventions that improved
function, although these were mostly assessed at later
times than in the present study. These interventions
have included environmental enrichment [56], inhibition
of production of microRNA-155 [57], indomethacin
treatment [26, 58], and long-term low-dose treatment
with minocycline [26].
Iba1-positive cells in peri-infarct tissue include both
resident microglia and tissue macrophages derived from
the circulation. However, at 3 days after stroke onset,
macrophages are typically only a minor component [17,
18, 59]. In our study, cells expressing CD68 were much
less numerous than total Iba1-positive cells and showed
a more restricted distribution, with most of the
CD68-positive cells localized to within 300 μm of the in-
farct. The distribution of CD68 expression could be ex-
plained if this was induced as a response to signals
generated in the infarct or if the immunopositive cells
were a separate population predominantly derived from
circulating monocytes. The latter possibility seems less
likely based on an early investigation demonstrating that
CD68 is mainly expressed by a subpopulation of resident
microglia at 3 days after photothrombotic stroke [52].
Either of these potential explanations would suggest that
the effects of minocycline on peri-infarct microglia are
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secondary to modifications of cells in the blood or in the
infarct. Minocycline can enter brain tissue after intraper-
itoneal injection but concentrations are much lower than
in the blood [60]. Thus, cells in the blood and probably
also within the infarct (where there is local breakdown
of the blood-brain barrier) will be influenced by higher
drug concentrations than resident microglia in the
peri-infarct tissue. An important role for blood-borne
monocytes in recovery from stroke has been suggested
by the finding that functional recovery was greatly re-
duced when entry of these cells to the damaged brain
was blocked [61], although similar effects were not seen
following depletion of monocytes/macrophages from the
circulation [62].
The limited effects of minocycline on the patterns of
Iba1 immunolabeling do not rule out the possibility that
the drug treatment had effects on the expression of
other proteins in the activated cells. There are few tech-
niques currently available that reliably detect relevant
changes in peri-infarct tissue (without contamination
from the infarct) and that allow the identification of the
cells involved. Recently, there has been considerable
interest in possible shifts in microglial properties be-
tween an M1 state that is pro-inflammatory and several
M2 states that exhibit more anti-inflammatory gene ex-
pression profiles [7, 63, 64], although such a classifica-
tion over-simplifies the responses of microglia in the
brain [65, 66]. The few studies examining peri-infarct
tissue indicate that genes commonly associated with
both the M1 and M2 states are expressed in response to
infarction with changes in some studies suggesting
greater relative expression of M2-related genes after the
first few days [67–72]. However, these investigations
have either been limited to the initial 24 h after stroke
[67, 68] or only examined individual markers associated
with the M1 or M2 state when specifically evaluating the
cells within the peri-infarct tissue [69–72]. Furthermore,
our assessment of one commonly used M2 marker,
arginase-1, in peri-infarct tissue detected substantial ex-
pression in cells other than microglia or macrophages
(Yew and Sims, unpublished). This observation, which
greatly complicates interpretation of studies using
arginase-1 as a marker, is consistent with other reports
showing expression mainly in neurons in normal brain
[73, 74] and upregulation in multiple cell types following
stroke [74]. Recently, arginase-1 was detected in
blood-derived macrophages in the ischemic core but not
in microglia in peri-infarct tissue following permanent
middle cerebral artery occlusion [59].
The improved rate of functional recovery induced by
the higher-dose treatment with minocycline was associ-
ated with a marked increase in the content of the astro-
cytic cytoskeletal proteins, vimentin, and GFAP,
indicating an increase in key features of reactive
astrogliosis. Astrocytes exhibit complex responses to in-
farct formation [12, 16]. The local proliferation of astro-
cytes and development of a glial scar immediately
adjacent to the infarct plays an important protective role
in limiting the spread of potentially damaging cells and
molecules from the infarct. In addition, reactive
peri-infarct astrocytes more distant from the infarct re-
lease a range of molecules, including some such as
trophic factors and cytokines that can promote neuronal
plasticity [12, 16]. Thus, the changes in the responses of
peri-infarct astrocytes could have contributed to an im-
proved environment for neuronal plasticity in the
peri-infarct tissue.
Minocycline did not significantly alter the marked
post-stroke increases in full-length neurocan, a proteo-
glycan that is also largely generated by astrocytes [45,
47]. Thus, not all components of reactive astrogliosis
were apparently equally affected by the treatment. In-
creases in full-length neurocan form part of changes in
perineuronal nets and the extracellular matrix that are
thought to promote the formation of new synaptic con-
nections in peri-infarct tissue [16, 75]). Our results sug-
gest that any beneficial effects of this response were not
likely to be greatly different between the
minocycline-treated rats and those treated with vehicle.
Astrocytes are not usually considered a primary target
for the actions of minocycline [28]. Thus, the changes
observed in these cells seem more likely to be secondary
to effects of the minocycline on other cells. Interestingly,
a previous study found that functional recovery was im-
proved by long-term treatment with lower doses of min-
ocycline following photothrombotic stroke and that this
was associated with an increase in the number of prolif-
erating astrocytes in peri-infarct tissue [26]. An in-
creased proliferation of peri-infarct astrocytes was also
associated with improved functional recovery due to en-
vironmental enrichment [76]. As with our findings, these
increases in aspects of reactive astrogliosis could have
contributed to alterations in the environment in
peri-infarct tissue that enhanced neuronal plasticity lead-
ing to better recovery.
Conclusions
Analysis of changes in Iba1 immunoreactivity following
photothrombotic stroke confirmed and extended previ-
ous reports demonstrating that morphological changes
in Iba1-positive cells are detectible in peri-infarct tissue
within the first few hours and that marked increases in
cell number develop in this tissue over the initial three
days. These investigations further revealed that morpho-
logical changes indicative of a reactive response spread
transiently to other parts of the cerebral cortex and that
there were initial losses of Iba1-positive cells in the
peri-infarct tissue, which preceded the delayed increases
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in these cells. The measures of circularity and area frac-
tion of Iba1 immunolabeling provided insights into core
features of the reactive responses of microglia and mac-
rophages in the peri-infarct tissue following stroke that
are potentially useful in monitoring the effects of treat-
ments on these cell populations.
Treatment with minocycline during the first 2 days
after photothrombotic stroke improved aspects of
neurological recovery without altering infarct volume.
However, this treatment had very limited effects on the
stroke-induced changes in the morphology and distribu-
tion of Iba1-positive microglia and macrophages in
peri-infarct tissue. Although these manifestations of
microglial activation have been reported to be modified
by minocycline in other studies, they do not seem to be
a primary target when treatment with this drug is lim-
ited to the early post-stroke period. Substantial reduc-
tions in the numbers of CD68-positive cells and
increases in features of reactive astrogliosis were seen in
peri-infarct tissue following minocycline treatment and
could have contributed to the improved outcome.
Additional file
Additional file 1: Figure S1. Additional morphological features of Iba1-
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area. Results are shown for ipsi02 and contra02 (left panels) and ipsi03 and
contra03 (right panels). The ROIs that were analyzed are identified in Fig. 2a.
N = 3 (7 days) or 4 (24 h); *p < 0.05 compared with the corresponding tissue
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